Teva Pharm second-quarter profit tops forecast, reaffirms 2020 outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Teva Pharma (TEVA) PT Raised to $11 at Cowen
August 5, 2020 1:04 PM EDTCowen analyst Ken Cacciatore raised the price target on Teva Pharma (NYSE: TEVA) to $11.00 (from $9.00) while maintaining a Market Perform rating.
The analyst commented, "Teva is performing as well as can be expected, with good cost reductions while still executing on the Austedo... More
